Formerly known as Advanced RNA Technologies LLC, Advirna LLC is a biotechnology company developing solutions for efficient delivery of polynucleotides in vivo. The firm recently (Spring 2020) reported having the capacity to generate self-deliverable siRNAs (sdRNAs) against COVID-19 genome, Ace2 receptor and any other gene of interest related to the virus. SdRNAs are fully modified siRNA conjugates that can transfect all cell types in vitro without transfection reagents. Same molecules can be used for in vivo delivery to many tissues, including lungs. Invaluable tools for the research in virus biology, the firm is developing a self-deliverable RNAi (sdRNAi) technology, based on the ability of chemically modified synthetic siRNA-conjugates penetrate cells without any additional formulations or methods. sdRNAi molecules efficiently transfect all cell types in vitro, including the most hard-to-transfect cells such as primary cells, and are functional in vivo. sdRNAs can be specifically delivered to liver, kidneys, brain and other tissues. sdRNAi technology provides a unique opportunity to study and modulate gene expression in vivo, in vivo target validation and disease modeling.The firm's technology platform is a key for developing of therapeutics based on the breakthrough in biology known as RNA interference (RNAi). This discovery opened a possibility to create a broad new class of human therapeutics. Advirnas proprietary RNAi platform based on self-deliverable RNAi technology has broad applications in Life Sciences. Self-deliverable RNAi provides researchers with new and efficient tools to specifically knock-down genes in living cells (both in vitro and in vivo) as well as to develop a pipeline of drug products to treat a wide array of human diseases.
